N2OFF's MitoCareX Bio Study Highlights SLC25A Biomarkers
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 22 Jan 26
N2OFF Inc. shares surged 69.09% in pre-market trading, reaching a 20-day high.
The catalyst for this movement is a new study co-authored by N2OFF's subsidiary MitoCareX Bio, which highlights SLC25A mitochondrial carriers as potential biomarkers for spaceflight-induced dysfunction. This research emphasizes their role in tumor metabolic adaptation and therapy resistance, integrating data from NASA and focusing on the ADP/ATP carrier AAC3, which could advance precision oncology.
This significant research could enhance N2OFF's position in the biotech sector, attracting investor interest and potentially leading to future collaborations or funding opportunities.
Analyst Views on NITO
About NITO
N2OFF Inc. is a clean tech company, which is engaged in providing sustainable solutions for agri- tech. The Company is focused on sustainable operations in various industries, such as agri-food tech, potent greenhouse gas emissions and solar projects, specialized in eco-crop protection that helps reduce food waste and ensure food safety while reducing the use of pesticides. Its solutions are based on a blend of food acids combined with certain types of oxidizing agent-based sanitizers and, in some cases, with fungicides at low concentrations. Its products have a synergistic effect when combined with these oxidizing agent-based sanitizers and fungicides. Its green solutions are capable of cleaning, sanitizing and controlling pathogens in fresh produce. The Company’s products include Processing Aids-SavePROTECT or PeroStar, which are an application added to fruit and vegetable wash water as a processing aid to peracetic acid to increase its efficiency against plant pathogens.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
